Liposomal or nanoparticle alpha-TEA reduced 66cl-4 murine mammary cancer burden and metastasis.
Efficacy of alpha-TEA formulated in liposome or biodegradable poly(D, L-lactide-co-glycolide) (PLGA) nanoparticle was evaluated in a BALB/c clone 66cl-4 mammary cancer mouse model using oral delivery. alpha-TEA-loaded liposome or nanoparticle at 5 mg, but not 2.5 mg/day, significantly reduced tumor burden (p < 0.001). Both formulations at 5 mg significantly reduced visible lung metastases and lymph node and lung micrometastatic tumor foci. Surprisingly, nanoparticle control mice exhibited significantly reduced tumor burden, lymph node, and lung micrometastatic tumor foci. Both formulations at 5 mg significantly enhanced tumor apoptosis. In summary, liposomes and nanoparticles are effective means for administering the lipophilic anticancer drug alpha-TEA.
Wang
Pei
P
Section of Molecular Genetics and Microbiology in the School of Biological Sciences, University of Texas, Austin, TX 78712, USA.
Jia
Li
L
Sanders
Bob G
BG
Kline
Kimberly
K
D000284:Administration, Oral; D000818:Animals; D000970:Antineoplastic Agents / Q000008:administration & dosage / Q000737:chemistry / Q000627:therapeutic use; D017209:Apoptosis / Q000187:drug effects; D001835:Body Weight / Q000187:drug effects; D045744:Cell Line, Tumor; D005260:Female; D019344:Lactic Acid / Q000737:chemistry; D008081:Liposomes / Q000138:chemical synthesis / Q000737:chemistry; D008175:Lung Neoplasms / Q000517:prevention & control* / Q000556:secondary; D008198:Lymph Nodes / Q000187:drug effects / Q000473:pathology; D008214:Lymphocytes / Q000187:drug effects / Q000473:pathology; D008325:Mammary Neoplasms, Experimental / Q000188:drug therapy* / Q000473:pathology; D051379:Mice; D008807:Mice, Inbred BALB C; D053758:Nanoparticles / Q000737:chemistry*; D010316:Particle Size; D010713:Phosphatidylcholines / Q000737:chemistry; D011100:Polyglycolic Acid / Q000737:chemistry; D000077182:Polylactic Acid-Polyglycolic Acid Copolymer; D011108:Polymers / Q000737:chemistry; D024505:Tocopherols / Q000008:administration & dosage / Q000737:chemistry / Q000627:therapeutic use*; D047368:Tumor Burden / Q000187:drug effects
D000970:Antineoplastic Agents; D008081:Liposomes; D010713:Phosphatidylcholines; D011108:Polymers; C015153:1,2-dilauroylphosphatidylcholine; D000077182:Polylactic Acid-Polyglycolic Acid Copolymer; D011100:Polyglycolic Acid; D019344:Lactic Acid; C488288:2,5,7,8-tetramethyl-2R-(4R,8R,12-trimethyltridecyl)chroman-6-yloxy acetic acid; D024505:Tocopherols